4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.84) per share and revenue of $0.53 million for the quarter.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). On average, analysts expect 4D Molecular Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
4D Molecular Therapeutics Price Performance
FDMT stock traded down $0.49 during trading on Tuesday, hitting $3.08. The stock had a trading volume of 368,602 shares, compared to its average volume of 831,809. The stock has a market capitalization of $142.68 million, a P/E ratio of -1.08 and a beta of 2.87. The company's 50-day moving average price is $3.45 and its two-hundred day moving average price is $5.38. 4D Molecular Therapeutics has a twelve month low of $2.24 and a twelve month high of $28.93.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on FDMT. Morgan Stanley decreased their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating for the company in a research note on Monday, January 13th. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Leerink Partners cut their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating for the company in a research report on Monday, January 13th. Weiss Ratings reiterated a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research report on Thursday, April 24th. Finally, BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $40.00 to $15.00 in a research report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $26.71.
View Our Latest Research Report on 4D Molecular Therapeutics
4D Molecular Therapeutics Company Profile
(
Get Free Report)
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
See Also
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
